0001104659-24-132177 Sample Contracts
ASCENTAGE PHARMA GROUP INTERNATIONAL INDEMNIFICATION AGREEMENTIndemnification Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations
This Indemnification Agreement (this “Agreement”) is dated [insert date], and is between Ascentage Pharma Group International, a company incorporated under the laws of the Cayman Islands (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
EXCLUSIVE OPTION AGREEMENT by and among Ascentage Pharma Group Corp Limited (亞盛醫药集團 (香港) 有限公司) Guangzhou Healthquest Pharma Co., Ltd. (广州顺健生物医药科技有限公司) Suzhou Ascentage Pharmaceutical Co., Ltd. (苏州亚盛药业有限公司) Ascentage Pharma Group International and...Exclusive Option Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations • New York
This Exclusive Option Agreement (this “Agreement”) is made as of June 14, 2024 (the “Effective Date”), by and among Ascentage Pharma Group Corp Limited (in Chinese, 亞盛醫药集團 (香港) 有限公司), a limited liability company incorporated under the laws of Hong Kong with a place of business at Unit B 17/F United Centre, 95 Queensway, Admiralty, HK (“Ascentage HK”), Guangzhou Healthquest Pharma Co., Ltd. (in Chinese, 广州顺健生物医药科技有限公司), a limited liability company incorporated under the laws of the Peoples Republic of China with a place of business at Room 2706, GIE Tower, 403 Huanshi Road East, Yuexiu District, Guangzhou, Guangdong, PRC (“Ascentage GZ”), and Suzhou Ascentage Pharmaceutical Co., Ltd. (in Chinese, 苏州亚盛药业有限公司), a limited liability company incorporated under the laws of the Peoples Republic of China, located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, PRC (“Ascentage SZ”), Ascentage Pharma Group International, an exempted company incorporated in the Cayman Islands with lim
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of June 20, 2024, by and between Ascentage Pharma Group International, an exempted company with limited liability incorporated in the Cayman Islands (the “Company”) and Takeda Pharmaceuticals International AG, a company incorporated under the laws of Switzerland (“Investor”).
March 1, 2022 Dear Dr. Wang,Scientific Advisory Board Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations
The purpose of this letter agreement (the “Agreement”) is to set forth the principal terms of the agreement that we have reached with respect to your serving on the Scientific Advisory Board of Ascentage Pharma Group Corp Limited and affiliates (the “Company”) and rendering consulting and advisory services relating to drug discovery and clinical development of novel anti-cancer therapeutics to the Company with respect to the Company’s efforts to develop one or more pharmaceutical products related to the treatment of certain forms of cancer and such other matters as may be agreed upon between the Company and you.
COLLABORATION AND LICENSE AGREEMENT BETWEEN ASCENTAGE PHARMA GROUP CORP LIMITED, GUANGZHOU HEALTHQUEST PHARMA CORP LIMITED, AND INNOVENT BIOLOGICS (SUZHOU) CO., LTD. JULY 14, 2021Collaboration and License Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of July [14], 2021, by and among Ascentage Pharma Group Corp Limited, a limited liability company incorporated under the laws of Hong Kong with a place of business at 9/F, Wah Yuen Building, 149 Queen’s Road Central, Central, Hong Kong (“ASCENTAGE HK”), Guangzhou Healthquest Pharma Co. Ltd., a limited liability company incorporated under the laws of the PRC with a place of business at Room 2706, GIE Tower, 403 Huanshi Road East, Yuexiu District, Guangzhou, People’s Republic of China (“ASCENTAGE GZ”, together with ASCENTAGE HK, “ASCENTAGE”) and Innovent Biologics (Suzhou) Co., Ltd., a limited liability company incorporated under the laws of the PRC with a place of business at 168 Dongping Street, Suzhou Industrial Park, Suzhou, the People’s Republic of China (“INNO”). ASCENTAGE and INNO may be referred to below individually as a “Party” and collectively as the “Parties.”
Guangzhou Shunjian Biomedical Technology Co., Ltd. Share Transfer Agreement December 2016Share Transfer Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations
THIS SHARE TRANSFER AGREEMENT is made and entered into on the 5th day of December, 2016 in Jiangsu Province amongst the following Parties:
US Headquarters 9400 Key West Avenue, Suite 220 Rockville, MD 20850 www.ascentagepharma.comSeverance Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations
This Severance Agreement (“Agreement”) establishes the terms of your severance benefits in the event your employment is terminated with Ascentage Pharma Group Inc. (“Ascentage” or “Company”), for the reasons set forth in this Agreement.
LICENSE AGREEMENT University of Michigan File [***]License Agreement • December 27th, 2024 • Ascentage Pharma Group International • Pharmaceutical preparations
This Agreement is effective as of December 1, 2010 (the “Effective Date”), between Ascentage Pharma Group (“LICENSEE”) having the address in Article 13 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (“MICHIGAN”). LICENSEE and MICHIGAN agree as follows: